HealthyRetired · Healthy Aging · Research and evidence
The idea is striking: remove unwanted proteins from the blood, and perhaps help the brain clear some of the proteins associated with Alzheimer's disease.
It is a genuine research question. But a widely shared story about a Swiss “nanofilter” goes further, claiming rapid cognitive improvements, a precise treatment schedule and insurance companies withholding a transformative therapy.
Before treating that story as a medical breakthrough, we need to distinguish the real research from the claims that remain unverified.
What I could—and could not—verify
As of 14 October 2026, the research checked for this article supports investigation of blood-based approaches. It did not establish the specific Swiss device and outcomes described in the circulating account.
| Claim in the circulating story | What the checked sources establish |
|---|---|
| A Swiss nanofilter selectively removes both amyloid-beta and tau | No named Swiss team, device or clinical publication was identified that verifies this particular claim |
| Many people with moderate dementia improve within weeks | Related studies exist, but they do not establish that result for the claimed device |
| Two sessions weekly for eight weeks, then monthly maintenance | This was not verified; a published plasma-exchange programme used a different schedule |
| The treatment costs less than long-term care | No verifiable device-specific cost or cost-effectiveness analysis was identified |
| Insurers deny access to protect profits | No evidence supporting that accusation was identified |
A claim repeated on several websites is not the same thing as several independent clinical studies. Lack of verification does not prove that no relevant device could exist, but it does mean we should not present this account as established fact.
Why removing proteins from blood might interest researchers
Alzheimer's disease involves abnormal amyloid-beta deposits and tau tangles, alongside other processes including inflammation, vascular problems and damage to neurons and their connections. It is not simply a dirty bloodstream. [1]
One proposed approach is the peripheral sink hypothesis: lowering some amyloid-beta in blood might influence movement or clearance of amyloid between the brain and the circulation. That is a hypothesis to test, not proof that cleaning blood automatically empties plaques from the brain.
The blood–brain barrier has specialised transport and clearance systems. Tau tangles inside brain cells and established neuronal damage are not equivalent to freely circulating proteins waiting to pass through a filter. [1]
A reduction in a blood biomarker therefore needs to be connected to meaningful clinical outcomes: memory, everyday function, quality of life and sustained benefit.
Real research: a small Japanese pilot
A 2022 first-in-human study from researchers in Japan investigated blood amyloid-beta removal in two people with early Alzheimer's disease and normal kidney function. The report described slight improvement or maintenance of cognitive function and no adverse events during the studied treatment. [2]
That is an exploratory finding. Two participants, without a randomised comparison group, cannot establish that the procedure reverses dementia or is safe and effective for a broader population. Repeated testing, natural variation and other factors can affect cognitive scores.
It also does not verify a Swiss device selectively removing both amyloid and tau. Different research projects should not be merged into one impressive-sounding story.
Real research: the AMBAR plasma-exchange trial
Another approach is plasma exchange with albumin replacement, studied in the AMBAR programme. Plasma is the liquid portion of blood; this procedure differs from a selective nanofilter trapping two named proteins.
The programme included a 14-month regimen: weekly plasma exchange for six weeks, followed by monthly low-volume exchange for 12 months. A report on laboratory outcomes describes 322 treated participants. [3]
The main trial publication reported less decline on an everyday-function measure in the pooled treatment groups. The pooled cognitive outcome showed a trend but did not reach conventional statistical significance: P = 0.06. [4]
Less decline compared with a control group is different from restoring lost abilities. Percentages describing relative slowing should not be translated into “this percentage of patients recovered.”
The study was sponsored by Grifols, a manufacturer of therapeutic albumin and immunoglobulin products, and some authors had company affiliations. That does not automatically invalidate the work, but it is relevant when assessing the evidence. [4]
Subsequent programme reports and clinical offerings also need evaluation on their own terms. They do not authenticate an unnamed Swiss nanofilter.
The comparison with medicines needs correcting too
The circulating story suggests that medicines only try to slow the formation of proteins, whereas filtration removes existing buildup. That is inaccurate.
Anti-amyloid medicines such as lecanemab target amyloid and reduce amyloid plaques in the brain. Their clinical benefits, risks and eligibility requirements are separate questions, and plaque reduction is not a cure. [5]
The appropriate comparison is between specific treatments tested in specific patients, rather than between “drugs” and “filters” as opposing categories.
Blood treatment is still a medical procedure
Procedures that circulate blood outside the body or exchange plasma require trained staff, vascular access and monitoring. Safety assessment must consider issues such as blood-pressure changes, bleeding, infection, reactions to replacement products and unintended removal of useful substances.
A sophisticated device description does not establish that healthy blood components are unaffected. A trial must demonstrate selectivity, safety and benefit rather than assume them from the word “nano.”
What about insurance and costs?
Dementia can create enormous costs for families. That makes affordable effective treatments important—and makes exaggerated promises particularly painful.
However, a cost estimate needs a country, year, stage of illness and definition of what is included. A single annual figure cannot describe every person with dementia, and it does not prove that a new intervention saves money.
Insurance coverage is also specific to the country, policy, procedure and indication. An experimental classification can reflect unresolved questions about benefit and safety. The claim that insurers are deliberately blocking a proven inexpensive cure is not supported by the evidence identified here.
Questions worth asking about a claimed breakthrough
Before considering a blood-filtration service for Alzheimer's disease, ask for the device's name, the research institution, trial registration, published results and regulatory status for the specific use.
Also ask how many people were studied, whether there was a control group, how long benefits lasted, what adverse events occurred, who funded the work, and what the total treatment and follow-up costs would be.
These questions help turn an exciting headline into something a dementia specialist can actually assess.
For HealthyRetired, the conclusion is one of interest with realistic expectations. Blood-based approaches deserve research. The material checked here does not justify describing the claimed Swiss nanofilter as a demonstrated way to reverse Alzheimer's disease.
A note for readers: This article is general information, not a recommendation to undergo blood filtration or change dementia treatment. Discuss new treatment claims with a qualified dementia specialist. Do not stop prescribed care because of an online account.
Sources
- National Institute on Aging: what happens to the brain in Alzheimer's disease.
- Hasegawa and colleagues: first-in-human blood amyloid-beta removal study, 2022.
- AMBAR: plasma-exchange regimen and laboratory parameters, 2023.
- Boada and colleagues: primary AMBAR trial results, 2020, with the full publication and funding disclosures.
- FDA: lecanemab approval and reduction of amyloid plaques.
Sources checked on 14 October 2026. This article distinguishes identified research from an unverified circulating claim. It does not assert that the search found every possible study, or establish availability or coverage in any particular country.